12.13.23
Gnosis by Lesaffre held the first meeting of its scientific advisory committee on vitamin K2, chaired by Leon Schurgers, a professor and researcher at Maastricht University specializing in vitamin K2. The Vitamin K2 Scientific Advisory Committee (K2SAC) is committed to exploring new research indications while also expanding the presence of thought leaders in biomedical research focused on K2.
Two new appointees, which were announced at the first meeting, were:
Stefanos Roumeliotis, MD from AHEPA University Hospital in Greece, a specialist in chronic disease research and statistical analysis driving the MenaQ7 K2 VIKIPEDIA study,
Sola Bahous, MD, PhD, MHPE, from Lebanese American University School of Medicine, an expert in arterial stiffness, pulse wave velocity, hypertension, and renal/kidney failure who is undertaking a migraine study involving MenaQ7 vitamin K2.
Roumeliotis and Bahous will join Schurgers and other K2SAC members, including Hogne Vik, MD, PhD, MBA, who serves as Gnosis by Lesaffre’s medical and scientific advisor, and Katarzyna Maresz, PhD, a fellow globally-recognized vitamin K2 expert.
The inaugural meeting was held in Lille, France in November, beginning with a lecture from Schurgers called “Healthy Aging and the Vitamin K2 Effect.” The overarching theme of the meeting was “Exploring the Future of Vitamin K2,” with panels covering the latest research associating vitamin K2 intake with emerging areas and applications.
“We are proud that our K2SAC is substantiated through such global expert participation,” said Jean-Francois Jeanne, substantiation and applications team manager at Gnosis by Lesaffre. “We see our K2SAC galvanizing a worldwide network of esteemed researchers who will focus on identifying specific population needs for K2 and leading the clinical evidence to demonstrate K2’s beneficial use in those areas.”
“I am honored by the invitation to join the Gnosis K2SAC, and this first meeting was a fantastic opportunity to share insights about this momentous time for Vitamin K2 research,” said Roumeliotis. “Growing the already substantial research supporting Vitamin K2 is essential for changing the state of global health. Collaborating with these esteemed individuals toward discovering and confirming new benefits and applications offers so much promise.”
Gnosis is supporting vitamin K2 research efforts worldwide outside of the scope of K2SAC as well. This includes clinical studies identifying new clinical indications for K2, as well as potential synergistic combinations.
“We are truly excited about the realm of new uses for K2 that the scientific advisory committee will incubate, resulting in more promising research in the future,” Jeanne said. “Our two new K2SAC members truly help round out the vitamin K2 research dream team, and our first meeting covered a lot of new ground to showcase the wide-ranging applications of K2 and health and wellness. This is such an exciting time.”
Two new appointees, which were announced at the first meeting, were:
Stefanos Roumeliotis, MD from AHEPA University Hospital in Greece, a specialist in chronic disease research and statistical analysis driving the MenaQ7 K2 VIKIPEDIA study,
Sola Bahous, MD, PhD, MHPE, from Lebanese American University School of Medicine, an expert in arterial stiffness, pulse wave velocity, hypertension, and renal/kidney failure who is undertaking a migraine study involving MenaQ7 vitamin K2.
Roumeliotis and Bahous will join Schurgers and other K2SAC members, including Hogne Vik, MD, PhD, MBA, who serves as Gnosis by Lesaffre’s medical and scientific advisor, and Katarzyna Maresz, PhD, a fellow globally-recognized vitamin K2 expert.
The inaugural meeting was held in Lille, France in November, beginning with a lecture from Schurgers called “Healthy Aging and the Vitamin K2 Effect.” The overarching theme of the meeting was “Exploring the Future of Vitamin K2,” with panels covering the latest research associating vitamin K2 intake with emerging areas and applications.
“We are proud that our K2SAC is substantiated through such global expert participation,” said Jean-Francois Jeanne, substantiation and applications team manager at Gnosis by Lesaffre. “We see our K2SAC galvanizing a worldwide network of esteemed researchers who will focus on identifying specific population needs for K2 and leading the clinical evidence to demonstrate K2’s beneficial use in those areas.”
“I am honored by the invitation to join the Gnosis K2SAC, and this first meeting was a fantastic opportunity to share insights about this momentous time for Vitamin K2 research,” said Roumeliotis. “Growing the already substantial research supporting Vitamin K2 is essential for changing the state of global health. Collaborating with these esteemed individuals toward discovering and confirming new benefits and applications offers so much promise.”
Gnosis is supporting vitamin K2 research efforts worldwide outside of the scope of K2SAC as well. This includes clinical studies identifying new clinical indications for K2, as well as potential synergistic combinations.
“We are truly excited about the realm of new uses for K2 that the scientific advisory committee will incubate, resulting in more promising research in the future,” Jeanne said. “Our two new K2SAC members truly help round out the vitamin K2 research dream team, and our first meeting covered a lot of new ground to showcase the wide-ranging applications of K2 and health and wellness. This is such an exciting time.”
